Dianthus Therapeutics

Forecast & Rating15 analysts currently cover Dianthus Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $141.21, about 31.9% upside from the current price of $107.04. Price targets range from $122.00 to $200.00 — a wide spread, showing clear disagreement over just how much Dianthus Therapeutics can rise. Historically, about 65.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Dianthus Therapeutics closely still see room for the stock to rise. Data as of Sep 4, 2026; for reference only and not investment advice.